Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Multiple Myeloma 3Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 1Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer 1Recurrence 1Patient Preference 1Neoplasms 1Lymphoma, Non-Hodgkin 1Inflammatory Breast Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1CD20-positive Hematological Malignancies 1Bile Duct Neoplasms 1Advanced Cancers 1

Interventions

Gemcitabine 11Cisplatin 10pembrolizumab 5Oxaliplatin 4durvalumab 3Magnetic Resonance Spectroscopy 3Leucovorin 3Fluorouracil 3tivozanib 2Specimen Handling 2Capecitabine 2zimberelimab 1trametinib 1tislelizumab 1quemliclustat 1pertuzumab 1olaparib 1irinotecan sucrosofate 1atezolizumab 1anlotinib 1Yttrium-90 1Tissue Adhesives 1Tegafur 1Stents 1S 1 (combination) 1Ritonavir 1Radiosurgery 1Pancreaticojejunostomy 1Pancreaticoduodenectomy 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bile Duct Neoplasms × Injections, Subcutaneous × 1 year × Clear all
NCT07036185 2025-06-25

A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors

Shanghai Bao Pharmaceuticals Co., Ltd.

Phase 1 Not yet recruiting
66 enrolled
BreastGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡